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We conducted a systematic review and meta-analysis to evaluate the evidence on 
herbal medicine for inducing or maintaining remission in ulcerative colitis (UC) and Crohn’s 
disease (CD). 
Methods: 
Eight databases were searched up to January 2017 for randomised controlled trials of herbal 
medicine as an adjunct to conventional medication in patients with IBD. Data were extracted 
to obtain risk ratio (RR) of failure of inducing or maintaining remission, with 95% confidence 
intervals (CI). Risk of bias was assessed using the Cochrane criteria. 
Results: 
Twenty-nine RCTs (24 UC, 5 CD) were included. In UC, herbal medicine was superior to 
placebo for clinical remission (RR of remission failure = 0.74, 95% CI: 0.59-0.93; I2 = 62%) and 
maintaining remission (RR of failure to maintain remission = 0.34, 95% CI: 0.17-0.67; I2 = 0%). 
Traditional Chinese patent medicine with standard therapy reduced the risk of no 
comprehensive remission by 19% compared to standard therapy alone (RR of no remission = 
0.81, 95% CI: 0.70-0.95; I2 = 0%). In CD, however, the effect of herbal medicine was 
significant neither for inducing nor maintaining remission (RR of remission failure = 0.57, 
95% CI: 0.24-1.33; I2 = 87%; RR of failure to maintain remission = 0.95, 95% CI: 0.60-1.52). 





































































An adjunctive herbal medicine to standard therapy appears effective with few adverse 
events in achieving and maintaining remission in UC, while there is a lack of supporting 
evidence for CD. Future high quality trials are warranted. 
 
Key words: Inflammatory bowel disease, ulcerative colitis, Crohn’s disease, herbal medicine, 
systematic review 
Abbreviations: IBD, Inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; 
CAM, complementary and alternative medicine; RCTs, randomised controlled trials; TCPM, 





































































Inflammatory bowel disease (IBD), where two principal types are Crohn’s disease 
(CD) and ulcerative colitis (UC), is characterised by a chronic inflammatory state of intestinal 
mucosa caused by dysfunction of the gastrointestinal (GI) immune system[1]. The 
distinguishing point between CD and UC is that CD is a transmural inflammatory disease that 
can affect any of the entire GI tract, whereas UC is a non-transmural inflammatory disease 
that affects only colon and rectum[2]. The incidence and prevalence of UC and CD have been 
prominent in western countries, however, recently the gradual increase in the incidence of 
UC has also been observed in developing countries[3]. Considering the trend that the 
occurrence of UC preceded that of CD by about 10 years, it is expected that the incidence of 
CD would also eventually increase[3]. 
IBD causes not only symptoms such as diarrhoea with stool containing mucus or 
blood, abdominal pain, and fever[1], but also complications from anaemia[4] to colorectal 
cancer[5]. In a majority of cases, the disease course of UC and CD is characterised by a 
sequence of flare-up episodes followed by remission periods[3], in other words, the 
alternation of active period and quiescent period. Thus, the treatment focuses on the 
induction of remission when the disease is active, and the maintenance of achieved 
remission[6, 7]. It depends on the extent and the severity of the disease, for example, 
patients with UC can be treated with medications from topical or oral 5-aminosalicylic acids 
(5-ASA) and steroids to thiopurines and anti-tumour necrosis factor (TNF) agents[7, 8], while 
patients with CD can be treated with drugs from budesonide or with systemic corticosteroids 
to anti-TNF agents[6]. Nevertheless, there are marked inter-individual and perhaps even 




































































most part[9, 10]. 
Due to the desire to avoid long-term medications and the fear of side effects[11], a 
number of IBD patients, clinicians, and researchers are paying more attention to 
complementary and alternative medicine (CAM). In North American and European studies, 
the current or past use of CAM to treat IBD ranges from 21-60%[11]. In IBD patients, herbal 
medicine in particular is the most preferred CAM intervention[12]. Several reasons for the 
high prevalence of herbal medicine use in this population may include a lack of perceived 
therapeutic response to standard therapy, increased recognition of adverse events (AEs) 
associated with medication while herbal medicine is generally considered safe or at least 
not recognised to cause serious side effects, and patients’ gaining a sense of control over 
their disease and management of symptoms[11, 12]. 
While several systematic reviews and meta-analyses on CAM and herbal medicine 
for IBD were performed[13-15], the evidence is inconclusive and limited due to language 
restriction. Because of the prevalent use of herbal medicine, the information concerning the 
efficacy and safety of it is important for both patients and clinicians. We have therefore 
performed a systematic review and meta-analysis to critically evaluate the effectiveness and 





































































The review process followed the Preferred Reporting Items for Systematic reviews 
and Meta-Analyses (PRISMA) statement[16].  
Search strategy 
A literature search was conducted using the following medical databases from 
inception to January 2017 without language restrictions: PubMed, EMBASE, CINAHL 
(Cumulative Index to Nursing and Allied Health Literature), AMED (Allied & Complementary 
Medicine Database), CNKI (China National Knowledge Infrastructure), KMBASE (Korean 
Medical Database), NDSL (National Digital Science Library), and OASIS (Oriental Medicine 
Advanced Searching Integrated System). The following key words as free texts and MeSH 
(medical subject headings) terms were used for building search strategies: inflammatory 
bowel disease(s); Crohn(‘s) disease(s); ulcerative colitis; Chinese traditional medicine; 
Chinese herbal drug(s); medicinal plant(s); plant extract(s); and phytotherapy. The key words 
were transformed considering the feature of each database (e.g. types of field or principal 
language) and combined with the filters for randomised controlled trials only. For PubMed, 
the following strategy was applied: ((("Colitis, Ulcerative"[MeSH] OR ulcerative colitis OR 
"Crohn Disease"[MeSH] OR Crohn* OR "Inflammatory Bowel Diseases"[MeSH] OR 
"inflammatory bowel disease" OR IBD) AND (Korean traditional medicine OR Chinese 
traditional medicine OR Chinese medicine [tiab] OR oriental traditional medicine OR east 
asian traditional medicine OR Kampo medicine OR phytotherapy OR Chinese herb* OR 
herbal drug* [tw] OR herbal medicine OR medicinal plant* OR herbal OR herbals OR 
herbalism))) AND (singl* OR doubl* OR tripl* OR trebl* OR blind* OR mask* OR placebo* OR 




































































addition, we also hand-searched the reference lists of relevant articles. 
 
Eligibility criteria 
We selected randomised controlled trials (RCTs) evaluating the efficacy of herbal 
medicine for the adjuvant treatment of IBD in adult patients (aged ≥ 18 years) who were 
diagnosed with UC or CD as defined in the original articles. Considering herbal medicine is 
usually taken in combination with conventional therapies, we included RCTs comparing 
herbal medicine with placebo or herbal medicine as an adjuvant therapy with conventional 
medicine if the identical types and dosages of medications were applied in both groups. 
Trials aiming to induce remission in an active period and maintain remission in a quiescent 
period were both included.  
We followed the definition of herbal medicine from ‘General guidelines for 
methodologies on research and evaluation of traditional medicine’ by World Health 
Organisation (WHO)[17]. As we sought RCTs comparing herbal medicine with placebo or 
herbal medicine used as an adjuvant therapy with conventional medicine, RCTs comparing 
herbal medicine alone with conventional medicine or no treatment were excluded. For a 
trial with more than two arms, only arms meeting the inclusion criteria were included in the 
analysis. The extent of Chinese herbal drugs was defined according to the 'Provisions for 
Drug Registration' by Chinese Food and Drug Agency (CFDA, available at 
http://eng.sfda.gov.cn/WS03/CL0768/61645.html). Within the extent, we only considered 
traditional Chinese patent medicine (TCPM) of which the total components were available 
and that were tested and listed in the CFDA and the Pharmacopoeia of the People’s Republic 




































































administration, we restricted the method of application to oral administration only, thus, 
injections or suppositories were excluded. 
Regarding outcome measures, only studies reporting on clinical outcomes of 
achieving or maintaining clinical remission were included. Studies reporting comprehensive 
remission consisting of a combination of clinical and endoscopic remission were also 
considered. We included studies that provided the definition of clinical or comprehensive 
remission. Although there was no limitation regarding the type of data - dichotomous or 
continuous - , only studies reporting on the induction or the maintenance of clinical or 
comprehensive remission as a form of dichotomous data, e.g. the proportion of patients 
who achieved or maintained clinical or comprehensive remission, were included in the 
meta-analysis. For the articles published in Chinese that did not use the term “remission”, 
the definition of remission followed the Consensus on the diagnosis and management of UC 
developed by the European Crohn's and Colitis Organisation (ECCO)[18], stating that 
‘complete resolution of symptoms and endoscopic mucosal healing’. In addition, AEs were 
summarised and tabulated. 
 
Study selection 
Two authors (S. Kim and B.-H. Lee) independently searched articles and made a list 
of retrieved articles in a Microsoft excel sheet. Two authors (B.-H. Lee and X. Zhang) 
searched Chinese databases and another (S. Lee) checked the list of retrieved articles. After 
overlapping studies were removed, articles were screened based on their title and abstract. 
Full texts of the retrieved articles then were collected and reviewed by three authors (S. Kim, 




































































discrepancy between the authors occurred, it was resolved by discussion with the 
corresponding author. The basic information on finally selected articles was tabulated. The 
variables extracted were year of publication, country, type of IBD and disease states, sample 
size, herbal medicine group intervention, control group intervention, outcomes including 
percentage of patients achieving or maintaining remission, and AEs. 
 
Risk of bias assessment 
Risk of bias assessment was conducted based on the Cochrane Collaboration’s risk 
of bias assessment tool, which consists of following 7 items related to the biases that could 
affect the outcomes: random sequence generation; allocation concealment; blinding of 
participants and personnel; blinding of outcome assessment; incomplete outcome data; 
selective outcome reporting; and other bias[19]. Each article was assessed and classified as 
one of the following three categories for each item: high risk; low risk; or unclear risk. Three 
authors (S. Kim, X. Zhang, and H. Lee) independently assessed each article according to the 
criteria and had a discussion to resolve the disagreements. 
 
Data syntheses and statistical analyses 
Statistical analyses and visualisations were conducted using the Review Manager 
programme (RevMan, version 5.1 for Windows; the Nordic Cochrane Centre, Copenhagen, 
Denmark). Studies were combined according to the type of IBD (i.e. UC or CD), and/or 
outcome measures. The primary outcome of interest was the percentage of patients who 
achieved or maintained clinical or comprehensive remission, depending on the disease state 




































































AEs associated with herbal medicine. The impact of herbal medicine on binary outcomes 
such as clinical remission at the end of treatment were expressed as risk ratio (RR) with 95% 
confidence intervals (CI), while continuous outcomes such as DAI were expressed as mean 
difference (MD) or standardised mean difference (SMD) with 95% CI. Data were pooled in a 
random effects model with inverse variance method as clinical characteristics of the studies 
were expected to be highly variable (e.g. disease state, treatment duration, outcome 
assessment time point).  
A chi-squared test was used to assess heterogeneity, with a significance level of P < 
0.1. To evaluate inconsistencies among trials, the I2 statistic was used. The I2 statistic 
indicates the proportion of variability among studies not explained by chance alone. The 
value of I2 statistic > 50% was considered to indicate substantial heterogeneity[20, 21]. The 
small study effect (i.e. a tendency for estimates of the intervention effect to be more 
beneficial in smaller studies) was also assessed with funnel plots when the analyses included 
more than 10 studies[22].  
We performed sensitivity analyses to evaluate whether the findings were affected if 
studies with a high/unclear risk of bias for randomisation and/or allocation concealment 
were excluded from pooling[23, 24]. As a subgroup analysis, we also explored the effect of 
TCPM as an adjunct to conventional medication as they usually contain multiple herbs and 
may produce different effects from single herbs. All these analyses are observational by 






































































A total of 3050 studies were identified through our searching. After 266 overlapping 
studies were removed, 2784 remaining articles were screened and 2254 studies were 
excluded based on the title and abstract. Subsequently, an assessment on the full-texts of 
530 remaining studies was conducted. Of these, 501 studies were excluded for the following 
reasons; 470 did not meet the inclusion criteria; 7 did not report on the name of 
medications specifically; 10 did not report relevant clinical outcomes; and 14 overlapped. 
Finally, 29 studies were finally included in this review and the process following PRISMA 
statement is depicted in Figure 1[16]. Of these, 24 studies (n=1,847) were about UC[25-48], 
while 5 studies (n=323) were on CD[49-53]. 
 
Study characteristics 
A total of 1,847 patients were involved in the studies of UC, with a sample size 
ranging from 20 to 224. Fourteen studies investigated the induction of remission for 
patients in active state[25, 27-35, 38, 40, 42, 45], four investigated the maintenance of 
remission in quiescent state[26, 41, 46, 48], and one study investigated both[47]. For the 
remaining five studies which did not clearly specify the disease state[36, 37, 39, 43, 44], an 
active state was assumed based on their inclusion criteria. Regarding the intervention, 12 
studies[26, 28, 29, 31, 34, 35, 41, 42, 45-48] investigated on the efficacy of single herbal 
drugs, such as Punica granatum peel extract syrub[29], silymarin (silybummarianum seed 
extract)[26], curcumin[28, 41], HMPL-004 (Andrographis paniculata ethanol extract, Indian 




































































most prevalent polyphenols in green tea leaves[35], GWP42003 (hard gelatin capsule 
containing cannabidiol and Δ9-tetrahydrocannabinol extracted from Cannabis sativa L.)[31], 
aloe vera gel[42], wheat grass juice[45], evening primrose oil[47], Vi-Siblinⓢ S granules 
containing Plantago ovata (Ispaghula) husk[48] and Plantago ovata seeds[46]. Apart from 
one study of Plantago ovata seed which was compared with mesalazine[46], the other 11 
studies used a placebo control. Meanwhile, the other 12 studies[25, 27, 30, 32, 33, 36-40, 
43, 44] were on TCPM and they were all published in Chinese language journals. Of these, 
four trials were on Chang yu ning granule, a combination of various herbs like Coptis 
Japonica, Scutellaria baicalensis, Pulsatilla chinensis, and Halloysite[27, 32, 33, 38]. Another 
three trials were on Bu pi yi chang pill consisting of Astragalus membranaceus, Codonopsis 
pilosula, Aucklandia lappa and Corydalis turtschaninovii, etc.[36, 37, 44]. The other five trials 
were on Kui jie ling granule[30, 40], Gu chang zhi xie wan[25], Chang yan ning syrup[39], and 
Yunnan Bai yao capsule[43], respectively. The duration of UC treatment varied from one to 
12 months (median 2 months). Among the 19 studies reporting the induction of remission, 
six studies calculated the proportion of patients who achieved clinical remission defined by 
Simple Clinical Colitis Activity Index (SCCAI)[54], Mayo score[55], UC disease activity 
index[56] or Suggestion on diagnosis and treatment of UC in integrated Chinese and 
Western Medicine[57], respectively. Two studies reported the proportion of patients who 
achieved comprehensive remission defined by Chinese national guidelines of diagnosis and 
treatment of IBD[58, 59], whereas other two studies used author-defined criteria which 
were not specifically reported. The other six studies reported only changes of clinical score 




































































studies on the maintenance of remission in UC all reported relapse of disease activity (Table 
1).  
Five studies involved total 323 patients with CD. Of these, three studies compared 
herbal medicine such as Boswelan (Boswellia serrata resin extract, Indian frankincense[50], 
HMPL-004[51], and SedaCrohnⓇ(Artemisia absinthium powder, wormwood)[53] to placebo. 
The other two studies examined the effectiveness of herbal medicine without a placebo. Of 
them, one was on SedaCrohnⓇ[52], and the other was on Shen ling bai zhu wan, TCPM[49]. 
All except one study[50] investigated the induction of remission in active state. The CD 
study duration ranged from 1.5 to 12 months (median 2 months) (Table 2).  
 
Risk of bias assessment 
For two studies published as a form of conference abstract [31, 51], items that were 
not fully reported were rated as 'unclear'. Nine of the included studies (31.0%) described 
the appropriate method of random sequence generation such as a random number 
table[25, 26, 32] or computer-generated randomisation sequence[29, 35, 41, 42, 46, 50] and 
only six studies (20.7%) adequately concealed group allocation[29, 34, 41, 45, 46, 50]. For 
blinding of participants and personnel, 15 studies which tested herbal medicine as an 
adjunct to conventional medication against conventional medication alone were considered 
as having a high risk of bias[25, 27, 30, 32, 33, 36-40, 43, 44, 46, 49, 52] while all the 
placebo-controlled studies were given a low risk of bias except one study using a placebo 
not identical to verum[47]. For blinding of outcome assessment, studies reporting outcome 
measures evaluated by unblinded participants and/or physicians considered unlikely to have 




































































attrition bias, studies which did not adopt intention-to-treat analyses were considered as 
having a high risk of bias. Regarding other sources of bias, 16 studies that neither 
appropriately describe random sequence generation nor allocation concealment methods, 
were given an unclear risk of bias[27, 28, 30, 33, 36-40, 43, 44, 47-49, 52, 53]. In addition, 
one study was rated as having a high risk of bias[45], because the numbers in the result 
table were not consistent. The summary and the supporting information for risk of bias 
assessment are provided in Figure 2 and Table S1. 
 
Effectiveness of herbal medicine 
UC (24 studies) 
A total of seven studies assessed the achievement of clinical remission[28, 31, 34, 
35, 38, 40, 42]. Five placebo-controlled studies testing GWP42003[31], curcumin[28], HMPL-
004[34], Polyphenon E capsules[35] and aloe vera[42] reduced the risk of failure to achieve 
clinical remission in active UC to 74% of what it would have been, but a substantial 
heterogeneity was detected (five studies, RR of failure to achieve clinical remission 0.74, 
95% CI [0.59, 0.93]; χ2 = 10.49, P = 0.03; I2 = 62%) (Figure 3a). When we restricted our 
analysis to trials with adequate randomisation and/or allocation concealment[34, 35, 42], 
the benefit remained significant (three studies, RR of failure to achieve clinical remission 
0.79, 95% CI [0.66, 0.95]; χ2 = 2.56, P = 0.28; I2 = 22%). However, two trials[38, 40] testing 
TCPM combined with standard therapy against standard therapy alone did not find 
significant difference in achieving clinical remission in active UC (two studies, RR of failure to 




































































Regarding the four studies reporting on comprehensive remission[36, 37, 43, 44], 
the meta-analysis demonstrated that herbal medicine significantly reduced the risk of 
failure to achieve remission by 45% (four studies, RR of failure to achieve comprehensive 
remission 0.81, 95% CI [0.70, 0.95]; χ2 = 0.95, P = 0.81; I2 = 0%) (Figure 3c). All of them 
compared TCPM combined with standard therapy with standard therapy alone: three tested 
Bu pi yi chang pill[36, 37, 44] and one was on Yunnan Bai yao capsule[43]. A sensitivity 
analysis was not performed as none of these four studies were given low risk of bias for 
adequate randomisation or allocation concealment.  
In three studies reporting maintenance of remission[26, 41, 46], compared with a 
placebo, herbal medicine such as silymarin[26] and curcumin[41], maintained remission of 
quiescent UC up to six months (two studies, RR of failure to maintain remission 0.34, 95% CI 
[0.17, 0.67]; χ2 = 0.25, P = 0.62; I2 = 0%) (Figure 3d) but Plantago ovata seeds[46] added to 
standard therapy failed to do so (RR of failure to maintain remission 0.85, 95% CI [0.42, 
1.72], P = 0.65). They all had low risk of bias for adequate random sequence 
generation/allocation concealment.  
The remaining ten studies that were not reporting remission data provided clinical 
score changes or the number of patients with any symptom improvements[25, 27, 29, 30, 
32, 33, 39, 45, 47, 48]. Of these, four studies were on single herbal medicine: in the study of 
Punica granatum peels, there was no significant difference of clinical response rate between 
treatment group and placebo group although the rate was higher in the treatment group 
(41.4% vs. 18.2%, P=0.055)[29]. In contrast, the wheat grass juice study demonstrated a 
significant improvement of DAI score in the treatment group compared to a placebo group 




































































group)[45]. Greenfield et al. tested the efficacy of evening primrose oil against a placebo: a 
significantly improved stool consistency was observed compared to a placebo, however, 
there was no significant difference in stool frequency and rectal bleeding[47]. Furthermore, 
a cross-over study on Plantago ovata husk showed the significantly higher improvement 
rate in treatment group (69% vs. 24%, P < 0.001)[48]. The other six studies were on TCPM 
added to standard therapy[25, 27, 30, 32, 33, 39]. Two studies investigating on Chang yu 
ning evaluated the changes of DAI score that were significantly improved in TCPM plus 
standard therapy group compared to standard therapy alone[32, 33]. The other four studies 
of Chang yan ning syrup/granule[27, 39], Gu chang zhi xie wan[25], and Kui jie ling 
granule[30] reported that significantly more patients reported improvement in the 
combination group compared to standard therapy group (four studies, RR of failure to 
achieve any improvement 0.35, 95% CI [0.21, 0.59]; χ2 = 1.18, P = 0.76; I2 = 0%). 
CD (5 studies) 
Three studies compared herbal medicine with a placebo[50, 51, 53]. Of these, 
HMPL-004 and SedaCrohnⓇ failed to reduce the risk of failure to achieve clinical remission 
(two studies, RR of failure to achieve clinical remission 0.57, 95% CI [0.24, 1.33]; χ2 = 7.67, P 
= 0.006; I2 = 87%)[51, 53] (Figure 4a). A sensitivity analysis was not conducted as it was not 
clear whether these two studies reported adequate randomisation/allocation concealment 
method. The other one study comparing Boswelan with a placebo also failed to maintain 
remission in quiescent CD (RR of failure to maintain remission 0.95, 95% CI [0.60, 1.52])[50] 
(Figure 4b).  
The other two studies compared herbal medicine given with conventional medicine 




































































achieve clinical remission (RR of failure to achieve clinical remission 0.25, 95% CI [0.07, 
0.90])[52], whereas another study on TCPM, Shen ling bai zhu wan, did not (RR of failure to 
achieve clinical remission 0.74, 95% CI [0.54, 1.02])[49]. 
 
Safety 
Twenty-two of 29 studies (75.9%) reported AEs[25-30, 32-35, 38, 39, 41, 42, 44-46, 
48-52]. A total of 314 cases of AEs associated with herbal medicine were reported in 19 
studies[25-30, 34, 35, 38, 39, 41, 42, 44-46, 48-51] and 3 studies reported that no AEs had 
occurred[32, 33, 52]. Of these, 280 cases (89.1%) were reported in 12 studies on single 
herbal medicine such as Punica granatum peel extract syrub[29], silymarin[26], 
curcumin[28, 41], HMPL-004[34, 51], Polyphenon E capsules[35], aloe vera gel[42], wheat 
grass juice[45], Vi-Siblinⓢ S granules[48], Boswelan[50], and Plantago ovata seeds[46], 
while seven studies on TCPM such as Gu chang zhi xie wan[25], Chang yu ning granule[27, 
38], Kui jie ling granule[30], Chang yan ning syrup[39], Bu pi yi chang pill[44] and Shen ling 
bai zhu wan[49] only reported 34 cases (10.9%). Most frequently reported AEs were GI 
symptoms like abdominal pain, nausea and vomiting, GI discomfort, diarrhoea or 
constipation. No study showed a significantly higher risk of AEs associated with herbal 
medicine than conventional medication, and eight studies reported that standard treatment 






































































Summary of main findings 
This systematic review and meta-analysis has summarised the currently available 
evidence for the effectiveness and the safety of various herbal medicines for achieving or 
maintaining remission in UC and CD. Out of 29 included studies in our review (24 UC and 5 
CD), 16 studies reporting clinical or comprehensive remission contributed data to the meta-
analysis.  
Single herbal medicines such as GWP42003, curcumin, HMPL-004, Polyphenon E 
capsules and aloe vera, appear more effective in achieving clinical remission in active UC 
compared with placebo, but TCPM in combination with sulfasalazine did not help achieve 
clinical remission of UC compared with sulfasalazine alone. Additional TCPM treatments to 
standard therapy were effective in inducing endoscopic as well as clinical remission in UC. 
For maintaining remission in quiescent UC, herbal medicines such as silymarin and curcumin 
were also effective. However, in CD, herbal medicines failed to achieve and maintain clinical 
remission. For safety, AEs associated with herbal medicine were mostly GI symptoms and 
few serious AEs were reported. The reported incidence of AEs has been similar between 
herbal medicine plus conventional medication group and conventional medication only 
group. 
 
Applicability of the evidence 
Herbal medicine is one of the most widely used CAM modalities in IBD patients[12, 
60]. Several reasons for the high prevalence of herbal medicine use in this population may 




































































of AEs associated with medication while herbal medicine is generally considered safe or at 
least not recognised to cause serious side effects, and gaining a sense of control over their 
disease and management of symptoms[61]. With the increase in IBD patients’ use of and 
researchers’ interests in herbal medicine, a number of clinical studies on herbal medicine for 
IBD have been conducted and accordingly, several systematic reviews and meta-analyses 
were published[13-15]. One meta-analysis concluded that herbal medicine demonstrated a 
promising effect for the induction of clinical remission, but a small number of 
heterogeneous studies made it difficult to draw convincing evidence[15]. Although our 
results broadly corroborate previous reviews, they included studies on single herbal 
medicine published mostly in English and German only. In other words, trials of Chinese 
herbal medicine have not been evaluated. Our systematic review is the first qualitative and 
quantitative analysis that included both studies on single herbal medicine and Chinese 
herbal medicine as an adjunct to conventional medication.   
There are several distinctive features of our systematic review. Traditional Chinese 
medicine or traditional East-Asian medicine has long taken a part in healthcare and been 
commonly utilised as a complementary or adjunctive treatment along with conventional 
medication in Asian countries including China, Japan, and Korea[1, 62]. However, because 
most of the studies on Chinese herbal medicine were published in Chinese, researchers have 
experienced difficulties in accessing and interpreting them. Our review could give 
researchers and clinicians new information on the efficacy and safety of complementary 
treatment of Chinese herbal medicine for IBD. Among innumerable Chinese herbal 
medicines for IBD, we only considered TCPM in our review because unlike other Chinese 




































































accepted and recommended by the CFDA. Additionally, we only included RCTs testing herbal 
medicine in conjunction with standard therapy because such practice is common in China 
and other East Asian countries, and we also considered it unusual or unlikely to achieve 
clinical response/remission with herbal medicine alone in other western countries as well.  
 
Risk of bias in the included studies 
Although our analysis indicates the possible benefit from herbal medicine for 
achieving clinical/endoscopic remission in IBD, careful interpretation of the results is 
necessary mainly due to high risk of bias in the included trials.  
It is well known that studies failing to report the method used to generate the 
randomisation sequence or to conceal group assignment tend to overestimate the effect of 
intervention under investigation[63, 64]. When we limited our analyses to studies which 
reported adequate randomisation and/or allocation concealment, the results were similar: 
herbal medicine reduced the risk of failure to achieve clinical remission by 26% and 21%, 
respectively. However, the number of studies becomes only three, making the evidence 
more limited. Moreover, only two out of 13 Chinese studies reported an adequate method 
of random number generation[25, 32] and allocation concealment was not mentioned in 
any of them. A recent research raised concern that Chinese trials were labelled as 
randomised, but in fact they might not be truly randomised[65]. The strength of the 
evidence in our review then could be weakened due to possible selection bias. 
Regarding blinding, only a quarter of the included studies secured blinding of 
participants and outcome assessment, which could directly lead to higher risk of 




































































risk of bias for outcome assessment blinding as we gave unclear risk of bias if a trial adopted 
outcome measures evaluated by unblinded participants and/or physicians whose blinding 
status was not clearly reported in the article. Nevertheless, the reason why more than a half 
of the studies (n = 15) failed to blind both participants and outcome assessment is probably 
the study design itself. All 15 trials compared herbal medicine plus standard therapy with 
standard therapy alone, i.e. A + B vs. B design. This type of design can be a down-to-earth 
approach on the one hand but also exaggerate the treatment effect on the other as a 
placebo effect cannot be controlled properly. All these should be considered if we are to 
adequately interpret the present results. 
 
Limitations of this review       
There are several limitations to our study. Probably the main weakness of this 
review arises from the quality of the included studies, with only 37.9% of the included 
studies reporting adequate randomisation and allocation concealment, and approximately a 
quarter of them being double-blinded. Rough reporting of AEs should also be considered 
when evaluating the overall benefit and harm. As conclusions of systematic reviews and 
meta-analyses are often limited by the quality of the primary studies, our review findings 
are not free from ‘garbage in, garbage out’ problems.  
Language restrictions in systematic reviews may have different impact on the results 
depending on the intervention of interest belongs to mainstream medicine or CAM[66]. 
Despite our extensive literature search without language restriction and inclusion of theses, 
we may have missed relevant studies, or this may reflect on the contrary, relatively small 




































































medicine for inducing clinical/endoscopic remission in IBD and this is consistent with the 
results from previous reviews[13-15], we had only 16 studies in our meta-analysis and three 
studies on CD. Therefore, the present findings mainly concern with UC and further high-
quality studies are warranted since SedaCrohnⓇ demonstrated a potential for inducing 
clinical remission in active CD[52, 53]. 
It is of note that the included studies were quite heterogeneous: each used 
different diagnostic criteria, a range of herbal medicine interventions and control types, and 
different outcome measures. We could not analyse how patient responses vary at different 
time points during the treatment period which might have been clinically informative. The 
most studied herbal medicine was tested in four RCTs at most. This may explain why 
previous reviews performed only qualitative analyses. We could not explore any sources of 
heterogeneity via subgroup analysis as there were only a small number of studies. Promising 
results in our review should be reproduced in future rigorous studies, e.g. curcumin, aloe 
vera gel, or Bu pi yi chang pill for clinical/endoscopic remission in active UC or SedaCrohnⓇ 
for clinical remission for active CD.    
Lastly, we only included Chinese trials of TCPMs in our review. Because the quality 
of Chinese herbal medicine could be influenced by a number of environmental factors[67],   
only TCPMs of which the ingredients are standardised and validated were considered. As 
there is an enormous variety of Chinese herbal medicine and its application also varies to a 
large extent, we believe that looking at the evidence from TCPMs can be a good starting 






































































To conclude, published evidence suggests that an adjunctive herbal medicine 
treatment to standard therapy appears effective in inducing and maintaining remission in 
active and quiescent UC with few side effects. There is a lack of supporting evidence on 
herbal medicine as a complementary therapy for inducing and maintaining remission in CD. 
Future trials of herbal medicine as an adjunct to conventional medication are warranted to 
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Fig. 1. PRISMA flow diagram of literature search[21].  
PRISMA, preferred reporting items for systematic reviews and meta-analyses. 
 
Fig. 2. Risk of bias summary of the included studies. 
+ indicates low risk of bias; -, high risk of bias; ?, unclear risk of bias[15]. 
 
Fig. 3. Forest plot of randomised controlled trials of herbal medicine added to standard 
therapy in UC.  
(a), Herbal medicine vs. placebo for inducing clinical remission in active UC; (b), TCPM added 
to standard therapy vs. standard therapy for inducing clinical remission in active UC; (c), 
TCPM added to standard therapy vs. standard therapy for inducing comprehensive remission 
in active UC; (d), Herbal medicine vs. placebo for maintaining remission in quiescent UC; UC, 
ulcerative colitis; M-H, Mantel-Haenszel; TCPM, traditional Chinese patent medicine. 
 
Fig. 4. Forest plot of randomised controlled trials of herbal medicine added to standard 
therapy in CD.  
(a), Herbal medicine vs. placebo for inducing clinical remission in active CD; (b), Herbal 
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Supplementary file 1: Table S1. Supporting information for risk of bias assessment. 
Supplementary file 2: Table S2. Adverse events reporting in the included studies. 
 
Figure 1
Click here to download high resolution image
Figure 2



















































Table S1. Supporting inform






































 and placebo syrup w
ere packed and alphabetically labeled 
in the sam










uote "Attending physician, patients, principal investigators, and data analyzer 
w











uote "A co-investigator w
ho w
as not involved in patients' recruitm
ent or 




are of the drug codes and cleared it 
































































ent (detection bias) 
Unclear risk 











The study described that data w
ere analyzed by using ITT approach, but the actual 









































edications unchanged and w
ere random
ly assigned in a 1:1 ratio... 
Sequential one-by-one blinded random
ization w
as perform
ed after stratification...” 
Table S1









"All participating physicians w
ere blinded to treatm
ent assignm
ent throughout the 
study except the clinician in charge of random
ization, w
ho did not participate in 
any assessm
ent of the patients." 
How












in (Cur-Cure, a 95%
 pure curcum
in preparation) and identical placebo 
capsules w
ere both purchased from











ary end point w
as the percentage of patients in clinical rem
ission at the 
end of the 1-m
onth treatm
ent, defined as SCCAI score ≤ 2. (Participants w
ere 




























ay not be a truly random
ised trial because there w













o description of random























ent (detection bias) 
Low
 risk 
The study used M
ayo score, w
hich consists of objective outcom
e (e.g., stool 
frequency, rectal bleeding and findings of proctosigm
oidoscopy) and subjective 
outcom
e assessed by physician w
ho w
















Because the study w
as not published as a form








Because the study w
as not published as a form










































ent (detection bias) 
Unclear risk 











ot all subjects w

























o description of random




























ent (detection bias) 
Unclear risk 
“Clinical response defined as a decrease from
 baseline in the total M
ayo Score by 
at least 3 points and at least 30%
 w
ith an accom
panying decrease in rectal 
bleeding subscore of at least 1 point or an absolute subscore of 0 or 1 point at 2 
m
onths. ... The prim
ary efficacy end point w
as clinical response at w
eek 8.” 
(Participants w
ere blinded but it is not clear w































































"All study personnel and participants w
ere blinded to treatm
ent assignm
ent for 






ent (detection bias) 
Low
 risk 
"All study personnel and participants w
ere blinded to treatm
ent assignm
ent for 
the duration of the study. O




ittee could see unblinded data, but none had any contact w








































eeting the inclusion criteria w
ere random
ized by a trial pharm
acist at 
Barts and the London N





















The placebo consisted of a liquid preparation containing flavourings, but no know
n 
















All histological grades w
ere assessed by the sam
e experienced histopathologist 
(RM










Although dropout and w
ithdraw
al rates w
ere slightly high, all analysis w
as 



























o description of random




















atching placebo control w
as used. 










eight kaolin and tragacanth, and tinted w
ith food color (Fast Green 
FCF). The placebo juice w
as prepared in a centralized location and distributed 
m











ent (detection bias) 
Low
 risk 
A disease activity index (DAI) w
as created by com
































Although the analyses w
ere confined to the 21 patients w
ho com
pleted the trial, 
the dropout rates w
ere not deem

























o description of random


















The placebo used in the study w










ent (detection bias) 
Unclear risk 
The participants reported the stool frequency on patient diary cards but it is not 
clear w
hether they w

























ay not be a truly random
ised trial because there w













o description of random























ent (detection bias) 
Unclear risk 











Although the analyses w
ere confined to the 29 patients w
ho com
pleted the trial, 
the dropout rates w
ere not deem















ay not be a truly random
ised trial because there w













































s and endoscopic results w
ere assessed by participants and physicians 
w





































o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w












o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w













































s and endoscopic results w
ere assessed by participants and physicians 
w



































o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w













o description of random
































s and endoscopic results w
ere assessed by participants and physicians 
w




















s and endoscopic evaluations w
ere reported w
ithout a reference, i.e. pre-





ay not be a truly random
ised trial because there w
ere no descriptions on 
random
isation m












o description of random
































s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w













o description of random
































s and endoscopic results w
ere assessed by participants and physicians 
w









as no description on w
ithdraw
als and dropouts and the analyses w
ere 
based on the participants w
ho com
















ay not be a truly random
ised trial because there w
ere no descriptions on 
random
isation m












o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w
ere no descriptions on 
random
isation m













o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


















s and endoscopic evaluations w
ere reported w
ithout a reference, i.e. pre-





ay not be a truly random
ised trial because there w
















o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w
























ay not be a truly random
ised trial because there w















o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


















s and endoscopic evaluations w
ere reported w
ithout a reference, i.e. pre-





ay not be a truly random
ised trial because there w

























as governed by a centrally held code to ensure an equal and 
random









as an open-label trial. (Herbal m
edicine w












ere not blinded w











ot all patients w





























o description of random





























s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w




































“Due to a low
 patient recruitm
ent rate and a com
paratively high dropout rate w
e 
decided to perform





A and B, but unknow
n allocation of drug and placebo to A and B. ... M
edication 
w











e soft gelatin capsule containing propylene glycol 
m
onolaurate and the excipients only. ... Blinding w




































Intention-to-treat and per-protocol analyses w










ere reported in detail although the trial w
















o description of random




























as assessed by using CDAI, w
hich consists of objective outcom
es 
(e.g., num
ber of liquid or soft stools and hem
atocrit) and subjective outcom
es 
(e.g., abdom
inal pain and general w


























Because the study w
as not published as a form













o description of random

















as an open-label trial. (Herbal m
edicine w












s and endoscopic results w
ere assessed by participants and physicians 
w


























ay not be a truly random
ised trial because there w















o description of random























ent (detection bias) 
Unclear risk 




























ay not be a truly random
ised trial because there w
















































































i, E. Elahi, M
. C
haharm


















clinical trial of silym


















































































































































































































































































































































































hn, E. Berry, W
heat g





























































































y 26 (1991) 747-750. 


























































35 (2015) 618-619. 













































































































































































r 17 (2010) 32. 
[19] G





n IL-8 of ulcerative co
litis in rats and
 related


















. Fan, Y.-S. Tao





































































































n of the therap




































































































































































































































































































































y 14 (2007) 87-95. 
 






















































































Increased appetite (3) 
Jia (2015)[3] 





inal pain (1) 
Bloating (1) 
M
ucous stool (1) 









inal pain (3) 
Bloating (2) 
M
ucous stool (3) 




















ination and the initiation 









ination and the initiation 



























































































inistered for sinusitis 
(1) 
Heartburn (4) 




Increased thirst (1) 
Increased diarrhoea (1) 
4 


























(75 to 1,200 m
g 
group and 74 to 
1,800 m
g group) 





serious ones (45 for 1,200 m
g group 
and 39 for 1,800 m
g group) 
75 













inal bulging, nausea, transient 

























als due to deterioration or 
a failure to im
prove sufficiently (6) 
Abdom
inal bloating (1) 
Pain in the feet (1) 










als due to deterioration or 
a failure to im
prove sufficiently (3) 
Bloating (2) 











orning appetite (2) 
Constipation (1) 
Increased vitality (5) 
12 







































































fort and lack 
of strength (3) 
22 
N
ausea, anorexia, and headache (6) 
Chang 
(2007)[19] 








































































































ber of AEs (9) 
38 
Total num







(containing 3.52 g 
of Ispaghula husk) 
2 
36 
Relapse of colitis (1) 
36 
Relapse of colitis (3) 
Abdom




















Hair loss (1) 
Abnorm
al liver function test results 
(0) 
Abnorm









Hair loss (1) 
Abnorm
al LFT results (0) 
Abnorm
al blood test results (0) 
Exanthem
ata (0) 


























ber of AEs (59) 
40 
Total num






















































urinary tract infections (33) 
Serious AEs: CD exacerbation (2) 
50 
Total num
































































































































































































































n 13 (2015) 1444-1449. e1441. 





















































i, E. Elahi, M
. C
haharm


















clinical trial of silym









































































































































































































































































































hn, E. Berry, W
heat g






































































































































































































r 17 (2010) 32. 
[18] G





n IL-8 of ulcerative co
litis in rats and
 related
 clinical research


















. Fan, Y.-S. Tao





































































































n of the therap





































































































































































































































































































































































y 14 (2007) 87
-95. 
 
